Bisantrene

比生群

Report date: 2025/08/07 17:57:42
NME

Base Information

Drug NameBisantrene
Drug Alias NameCyabinZantreneOrange CrushXANTRENEBisantrene hydrochloride +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAlpha-ketoglutarate-dependent dioxygenase FTO inhibitors
TargetsAlpha-ketoglutarate-dependent dioxygenase FTO
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesLeukemia, Myelomonocytic, Chronic +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaFranceIsrael +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesWyeth Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesRace Oncology Ltd
Inactive CompaniesPfizer Inc
Active IndicationsSolid tumoursLeukemia, Myeloid, Acute
Inactive IndicationsMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicHematopoietic stem cell transplantation (HSCT)

Other Information

ATC CodeN/A
Related LinksN/A